Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Torisel

- PMLiVE

Roche’s Avastin cuts progression of aggressive brain cancer

Supports potential new indication for oncology medicine

Sanofi reception

Sanofi’s Lyxumia and Zaltrap backed for European approval

Company on course to expand its diabetes and cancer portfolio

- PMLiVE

WHO launches framework to monitor non-communicable diseases

Will measure success of efforts to reduce rates of cancer, diabetes, lung conditions and heart disease

- PMLiVE

NICE rejects Pierre Fabre’s bladder cancer drug Javlor

Says drug received final draft 'no' because pharma company failed to prove efficacy

- PMLiVE

Pfizer’s arthritis hope Xeljanz gets US approval

Could present a major challenge to existing biologic treatments like Humira and Orencia

- PMLiVE

Pfizer helps fund biotech venture from former researchers at closed Kent facility

Ziarco headed by former Pfizer chief scientific officer, allergy and respiratory research, Mike Yeadon

- PMLiVE

Roche’s Avastin cleared in EU for recurrent ovarian cancer

Becomes first biologic to win approval for platinum-sensitive ovarian cancer

- PMLiVE

More action needed to prevent AF-related strokes

Bayer-sponsored report says Europe is heading for a ‘stroke crisis’

- PMLiVE

GSK, Pfizer and Shionogi rewrite HIV joint venture terms

Comes ahead of first regulatory submissions for lead drug candidate dolutegravir

- PMLiVE

Pfizer’s Elvira Sanz named next president of Farmaindustria

Will lead Spanish pharma industry body for the new two years

- PMLiVE

The first public presentation of human Lipitor data

This month In 1994: The first public presentation of human Lipitor data

- PMLiVE

Pfizer pays $680m to buy ADHD drug developer NextWave

Portfolio includes once-daily Quillivant XR

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links